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therapy [PDT], photothermal therapy, radiofrequency 
interstitial tumor ablation [RITA], focal laser ablation [FLA]) 
but only limited data have been published on the primary 
PPI. From the technique point of view, PPI is now feasible 
with focal BRT and EBRT. The majority of series include both 
low-dose-rate (LDR) and HDR BRT and only recently 
feasibility of PPI by EBRT has been reported4,5. According to 
the international&interdisciplinary panel consensus6, the 
selection criteria for focal therapy include unilateral low-to-
intermediate risk disease < cT2a (prostate size, tumor 
volume, and topography depend on the ablative technology 
used). As for any other focal therapy, focal RT remains 
investigational until numerous questions are answered: initial 
diagnostic tools to identify DIL (imaging, biopsy), technical 
parameters of focal therapy, follow-up exams and 
scheduling, tumor control (patterns of failure) and toxicity 
profile including erectile dysfunction and quality of life (in 
particular, compared to the whole prostate therapy), 
response evaluation and failure definition (nadir+2 is used, 
but in some series biopsy is routinely performed), salvage 
therapy and cost-benefit. Ongoing trials like NCT013549951 
and NCT00807820 will contribute to further assessment of 
PPI. 
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Purpose/Objective: Image-guided IMRT (IG-IMRT) is 
associated with significant dose reductions to organs at risk 
(OAR) compared to 3D-conformal radiotherapy (3D-CRT) in 
prostate cancer patients. However, clinical data identifying 
the benefits of IG-IMRT in patients treated in daily practice 
are scarce. We compared dose distributions and acute 
gastrointestinal (GI) and genitourinary (GU) toxicity levels of 
prostate cancer patients treated to 78 Gy (39x 2 Gy) with 
either IG-IMRT or 3D-CRT.  
Materials and Methods: A total of 215 patients treated to 78 
Gy with 3D-CRT within a dose escalation trial (1997-2003) and 
260 patients treated with IG-IMRT to 78 Gy in the standard 
arm of a hypofractionation trial (2007-2010) are included in 
this analysis. Applied margins were 10mm (3D-CRT) and 5-
8mm (IG-IMRT), and both used 0 mm towards the rectum for 
the 10 Gy boost. Dose surface histograms of anorectum, anal 
canal and bladder were compared. Furthermore, in both 
trials identical toxicity questionnaires were prospectively 
distributed at baseline, at fraction 20 and 30 and 90 days 
after treatment. Slightly modified RTOG grade ≥1, grade ≥2 
and ≥3 toxicity endpoints were derived directly from the 
patient-reported questionnaires. Univariate (UV) and 
multivariate (MV) binary logistic regression was performed. 
Results: IG-IMRT resulted in significant lower median volumes 
receiving 5- 75Gy (all p values <0.001) for anorectum (Figure 
1a), anal canal and bladder. The mean dose to the anorectum 
was 34.4 Gy vs. 47.3 Gy, 23.6 Gy vs. 44.6 Gy for the anal 
canal and 33.1 Gy vs. 43.2 Gy for the bladder (all p<0.001). 
Acute toxicity reached a maximum at fraction 30 for most 
endpoints, as shown for proctitis grade ≥2/ ≥3 in Figure 1b. 
After adjusting for risk factors at MV analysis, IG-IMRT 
resulted in significantly lower overall GI grade ≥2 RTOG 
toxicity (29% vs. 49%, p=0.002, odds ratio (OR) 0.49) and 
overall GU grade ≥2 toxicity (38% vs. 48%, p=0.009, OR 0.59). 
Significantly lower incidences were reported for the 
endpoints abdominal cramps (34% vs. 46%), tenesmus (49% vs. 
62%), mucous discharge (47% vs. 62%), grade ≥2 proctitis (27% 
vs. 44%), stool frequency ≥6/day (8% vs 19%), and urinary 
frequency ≥12/day (19% vs. 30%) (p values 0.002-0.028). 
Comparable incidences (p values >0.05) were found for 
incontinence (both 27%), diarrhea (both 14%), rectal blood 
loss (12% vs. 20%) and nycturia ≥5/night (23% vs. 27%).  
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Conclusions: To our knowledge, this is the first paper 
addressing patient-reported acute GI and GU toxicity data 
from large prospective studies. We identified clinically 
relevant reductions in acute GI and GU toxicity for patients 
treated with IG-IMRT compared to 3D-CRT. This is the result 
of significantly lower doses to OARs, achieved by improved 
techniques and tighter margins. Since delivered dose to OARs 
as well as acute toxicity itself are known predictors of late 
toxicity, we expect this will eventually translate in lower late 
toxicity levels.  
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Purpose/Objective: According to European and American 
guidelines, treatment options after radical prostatectomy are 
adjuvant radiotherapy or early salvage radiotherapy (RT). In 
both cases, only prostate bed irradiation is recommended 
because any remaining tumor or local recurrence are most 
frequently located at this site. Recurrence in other sites can 
therefore be overlooked. In this study, we aimed to evaluate 
the incidence and location of visible recurrence on pelvic 
multiparametric MR (mpMR), to define the radiological 
criteria of local recurrence and lymph node spread after 
radical prostatectomy, and to determine the association of 
clinical and pathologic variables with imaging results. 
Materials and Methods: We retrospectively reviewed the 
clinical records and mpMR studies of 70 patients with PSA 
recurrence after radical prostatectomy. To investigate any 
association between clinical and pathological variables with 
imaging results, we recorded initial PSA, pT stage, 
pathological Gleason score, presence and location of 
extracapsular extension, vesicle involvement, margin status, 
number of positive margins, postoperative PSA, PSA at the 
time of MRI, PSA doubling time and open versus laparoscopy 
or robotic prostatectomy. Statistical analysis was performed 
using T-test and univariate and multivariate studies. 
MR protocol included T2 weighted TSE sequences, diffusion-
weighted sequences, calculation of apparent diffusion 
coefficient values, and dynamic contrast-enhanced MR with 
time curves generated from regions of interest. 
Results: mpMR was positive in 33/70 patients. We found no 
statistically significant differences between patients with 
positive or negative mpMR studies for any variables. Local 
recurrence occurred in 27 patients: perianastomotic (19), 
periurethral (1), right posterior to the bladder (3), left 
posterior to the bladder (1), right seminal vesicle bed (1), 
left seminal vesicle bed (1), and penile bulb (1). mpMR 
detected positive lymph nodes in 7 patients (14 
regions)(10%): right external iliac (5), left external iliac (4), 
right common iliac (2), left internal iliac (1), right obturator 
(1) ,and left obturator (1). 
Lower PSA doubling time was associated with positive lymph 
nodes (5.83 vs 17.35 months (p=0.05). Lymph node and local 
recurrence showed the same functional parameters in mpMR. 
Conclusions: Nearly half the patients with PSA-recurrence 
after radical prostatectomy had visible disease in mpMR. 
Incidence of positive lymph nodes should be considered when 
planning adjuvant or salvage radiotherapy. We recommend 
mpMR-guided RT rather than blind salvage RT.  
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Purpose/Objective: A subset of patients experience a PSA 
recurrence (rPSA) following radical prostatectomy. 
Radiotherapy can salvage those patients, provided that all 
disease is encompassed within the planning target volume 
(PTV) and a sufficient radiation dose is delivered. We 
hypothesized that these requirements can be achieved more 
adequately with MRI-guided radiation treatment planning. 
Materials and Methods: From January 2009 to April 2014, 238 
patients with rPSA were referred to our department for 
salvage radiotherapy. According to protocol, patients 
received a planning CT without IV contrast as well as a 
planning MRI in treatment position. MRI consisted of T1-, T2-, 
and diffusion-weighted (with an apparent diffusion 
coefficient (ADC) map) sequences. Dose to the prostate bed 
was 66.0 Gy in 33 fractions for all patients, delivered through 
intensity-modulated radiotherapy (IMRT). All MRI scans were 
reviewed by an experienced uro-radiologist. 
Results: Patients with a rPSA ≥ 5.0 µg/L or proven local 
recurrence were excluded from this analysis (n = 16). Of 222 
evaluable patients, 183 patients received both a planning CT 
and MRI while 39 patients only received a planning CT for 
various reasons. Patients were referred a mean 33.2 months 
(range: 6 – 161 months) after radical prostatectomy for a pT1 
(n = 1), pT2 (n = 108), pT3 (n = 68), or pT4 (n = 1) prostate 
adenocarcinoma (see Table). Median rPSA value at time of 
